{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:26:17Z","timestamp":1792895177705,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jpba.2024.116082","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T03:50:39Z","timestamp":1709783439000},"page":"116082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Multiplexed quantification of venlafaxine and metabolites in human plasma by liquid chromatography-tandem mass spectrometry"],"prefix":"10.1016","volume":"243","author":[{"given":"Aashish","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ayala-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyana Y.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116082_bib1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2024.116082_bib2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1185\/03007991003772096","article-title":"Prescription patterns of antidepressants: findings from a US claims database","volume":"26","author":"Milea","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpba.2024.116082_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107151","article-title":"Venlafaxine can reduce the migraine attacks as well as amitriptyline: a noninferiority randomized trial","volume":"214","author":"Hedayat","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jpba.2024.116082_bib4","first-page":"117","article-title":"Venlafaxine and desvenlafaxine in the management of menopausal hot flashes","volume":"9","author":"Johnson","year":"2011","journal-title":"Pharmacy Pract."},{"key":"10.1016\/j.jpba.2024.116082_bib5","first-page":"1999","article-title":"Treatment of neuropathic pain with venlafaxine: a systematic review","volume":"18","author":"Aiyer","year":"2017","journal-title":"Pain. Med."},{"key":"10.1016\/j.jpba.2024.116082_bib6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0269881120936509","article-title":"Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine","volume":"34","author":"Scherf-Clavel","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpba.2024.116082_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pnpbp.2018.04.014","article-title":"Reduced clearance of venlafaxine in a combined treatment with quetiapine","volume":"85","author":"Paulzen","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpba.2024.116082_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpba.2024.116082_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bcpt.12796","article-title":"Therapeutic drug monitoring of venlafaxine in an everyday clinical setting: analysis of age, sex and dose concentration relationships","volume":"121","author":"Hansen","year":"2017","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"10.1016\/j.jpba.2024.116082_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/YIC.0b013e32834ce13f","article-title":"Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies","volume":"27","author":"De Silva","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpba.2024.116082_bib11","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.transproceed.2009.09.022","article-title":"Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report","volume":"41","author":"Detry","year":"2009","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.jpba.2024.116082_bib12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1097\/PAS.0b013e31826af296","article-title":"Venlafaxine-induced cholestatic hepatitis case report and review of literature","volume":"36","author":"Stadlmann","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jpba.2024.116082_bib13","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.forsciint.2016.05.030","article-title":"Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism","volume":"266","author":"Castanares-Zapatero","year":"2016","journal-title":"Forensic Sci. Int"},{"key":"10.1016\/j.jpba.2024.116082_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2125.2007.02849.x","article-title":"Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases","volume":"64","author":"Howell","year":"2007","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2024.116082_bib15","doi-asserted-by":"crossref","unstructured":"A.D. Wilson, C. Howell, W.S. Waring, Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series, 2007. \u3008www.medcalc.be\u3009.","DOI":"10.2131\/jts.32.97"},{"key":"10.1016\/j.jpba.2024.116082_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2217\/pgs-2019-0031","article-title":"Venlafaxine pharmacogenetics: a comprehensive review","volume":"20","author":"Suwa\u0142a","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpba.2024.116082_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2012.12.020","article-title":"A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine","volume":"226","author":"Jornil","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2024.116082_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/YIC.0000000000000268","article-title":"Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine","volume":"34","author":"Kowalewski","year":"2019","journal-title":"Int Clin. Psychopharmacol."},{"key":"10.1016\/j.jpba.2024.116082_bib19","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00216-014-7619-9","article-title":"Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS\/MS","volume":"406","author":"Berm","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116082_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchromb.2010.01.007","article-title":"Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study","volume":"878","author":"Qin","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116082_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2008.05.024","article-title":"LC-MS\/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine concentrations in both matrices","volume":"48","author":"de Castro","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116082_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","article-title":"Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting","volume":"24","author":"Reis","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116082_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jchromb.2006.12.019","article-title":"High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS\/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma","volume":"850","author":"Liu","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116082_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jchromb.2018.04.033","article-title":"Validation of an LC-MS\/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study","volume":"1087\u20131088","author":"Gu","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116082_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpba.2010.03.043","article-title":"Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction","volume":"53","author":"Kingb\u00e4ck","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116082_bib26","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Bioanalytical Method Validation Guidance for Industry,, 2018th ed., Rockville, MD, USA, 2018. \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/default.htm\u3009.\u3008http:\/\/wwwfda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/default.htm\u3009.."},{"key":"10.1016\/j.jpba.2024.116082_bib27","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116082_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-200208000-00014","article-title":"Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting","volume":"24","author":"Reis","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116082_bib29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","article-title":"The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: Exploring predictive biomarkers for treatment outcomes","volume":"232","author":"Jiang","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpba.2024.116082_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-017-0173-2","article-title":"Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)","volume":"18","author":"Lloret-Linares","year":"2017","journal-title":"BMC Pharm. Toxicol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:04:53Z","timestamp":1715285093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0731708524001225"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116082","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiplexed quantification of venlafaxine and metabolites in human plasma by liquid chromatography-tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116082"}}